Cronos Group Inc.
HealthcareNASDAQ:CRON · NASDAQ Global Market
-$0.07 today
Vol 0.85M · Avg 1.52M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-0.9%
avg 0.6%
ROIC
-0.1%
avg -7.2%
ROA
-0.8%
avg -0.2%
Analysis
ROIC is currently the strongest return metric at -0.1% versus its period average of -7.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael Ryan Gorenstein | President, Chief Executive Officer & Chairman | $2.13M | — | 39 | $13.34M | 3.57% |
Anna Shlimak | Chief Financial Officer | $795,480.00 | — | 40 | $368,362.00 | 0.10% |
Jeffrey David Jacobson | Chief Growth Officer | $765,870.00 | — | 40 | $484,681.00 | 0.13% |
James Holm | Executive Officer | $712,288.00 | — | 42 | $313,882.29 | 0.08% |
Adam Wagner | General Manager of Cronos Israel | $637,214.00 | — | 43 | $103,987.00 | 0.03% |
Shannon Buggy | Senior Vice President & Global Head of People | $530,015.00 | — | 56 | $187,501.00 | 0.05% |
Harrison Aaron | Senior Director of Investor Relations & Corporate Development | — | — | — | — | — |
Terry Gregory-Joseph Doucet | General Counsel & Corporate Secretary | — | — | 36 | $110,588.00 | 0.03% |
Arye Weigensberg | Senior Vice President and Head of Research & Development | — | — | 43 | $211,555.00 | 0.06% |
Jared Matthew Kenost | Principal Accounting Officer, Vice President & Controller | — | — | — | $63,354.00 | 0.02% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +55.4% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +55.4% (14yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
$1.40B
IRadimed Corporation
NASDAQ:IRMD
$1.20B
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
$1.12B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Pacira BioSciences, Inc.
NASDAQ:PCRX
$904.31M
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
$885.83M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$827.07M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$620.83M
Embecta Corp.
NASDAQ:EMBC
$183.92M
Who manages CRON?
Cronos Group Inc. (CRON) lists 10 active executives. The top listed executive is Adam Wagner, General Manager of Cronos Israel.
Are CRON insiders buying or selling?
Recent insider activity shows net selling of $4.93M.
Explore More
Continue the stock analysis
Jump to another research area for this company.